Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder, Overactive | 7 | 2023 | 87 | 3.360 |
Why?
|
| Suburethral Slings | 5 | 2020 | 73 | 2.820 |
Why?
|
| Urinary Incontinence | 4 | 2023 | 206 | 2.260 |
Why?
|
| Lower Urinary Tract Symptoms | 3 | 2022 | 59 | 2.090 |
Why?
|
| Urology | 3 | 2023 | 110 | 1.950 |
Why?
|
| Urinary Incontinence, Stress | 5 | 2017 | 192 | 1.670 |
Why?
|
| Urinary Bladder Neck Obstruction | 3 | 2022 | 21 | 1.650 |
Why?
|
| Prostatic Hyperplasia | 4 | 2016 | 88 | 1.650 |
Why?
|
| Laser Therapy | 4 | 2016 | 142 | 1.620 |
Why?
|
| Social Media | 2 | 2023 | 79 | 1.490 |
Why?
|
| Urologic Surgical Procedures | 6 | 2023 | 146 | 1.340 |
Why?
|
| Urodynamics | 5 | 2022 | 122 | 1.320 |
Why?
|
| Diabetes Complications | 2 | 2020 | 207 | 1.280 |
Why?
|
| Prostatectomy | 4 | 2016 | 471 | 1.230 |
Why?
|
| Prostatism | 3 | 2010 | 5 | 1.130 |
Why?
|
| Thulium | 2 | 2016 | 2 | 1.080 |
Why?
|
| Lasers, Solid-State | 2 | 2016 | 8 | 1.070 |
Why?
|
| Pelvic Organ Prolapse | 4 | 2023 | 139 | 1.070 |
Why?
|
| Uterine Prolapse | 3 | 2023 | 77 | 1.000 |
Why?
|
| Transurethral Resection of Prostate | 3 | 2014 | 9 | 0.950 |
Why?
|
| Urinary Bladder | 4 | 2022 | 246 | 0.950 |
Why?
|
| Postoperative Complications | 7 | 2018 | 2207 | 0.940 |
Why?
|
| Surgery, Plastic | 1 | 2023 | 42 | 0.900 |
Why?
|
| Nocturia | 1 | 2022 | 19 | 0.880 |
Why?
|
| Cystitis, Interstitial | 1 | 2023 | 53 | 0.880 |
Why?
|
| Spinal Cord Injuries | 1 | 2022 | 54 | 0.820 |
Why?
|
| Electric Stimulation Therapy | 1 | 2022 | 51 | 0.820 |
Why?
|
| Muscarinic Antagonists | 3 | 2010 | 55 | 0.790 |
Why?
|
| Urinary Tract Infections | 5 | 2022 | 76 | 0.760 |
Why?
|
| Vagina | 3 | 2022 | 161 | 0.760 |
Why?
|
| Hysterectomy | 2 | 2022 | 146 | 0.730 |
Why?
|
| Phenylpropanolamine | 2 | 2010 | 15 | 0.730 |
Why?
|
| Cresols | 2 | 2010 | 17 | 0.720 |
Why?
|
| Comprehension | 1 | 2020 | 79 | 0.720 |
Why?
|
| Benzhydryl Compounds | 2 | 2010 | 48 | 0.710 |
Why?
|
| Video Recording | 1 | 2020 | 190 | 0.700 |
Why?
|
| Smoking | 5 | 2007 | 609 | 0.680 |
Why?
|
| Spinal Dysraphism | 1 | 2018 | 17 | 0.670 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 25 | 0.660 |
Why?
|
| Humans | 50 | 2023 | 86678 | 0.640 |
Why?
|
| Female | 33 | 2023 | 44550 | 0.630 |
Why?
|
| Middle Aged | 26 | 2020 | 25040 | 0.610 |
Why?
|
| Urinary Bladder Diseases | 1 | 2017 | 41 | 0.610 |
Why?
|
| Cystocele | 1 | 2017 | 7 | 0.610 |
Why?
|
| Surgical Mesh | 2 | 2022 | 116 | 0.610 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 351 | 0.600 |
Why?
|
| Aged | 19 | 2022 | 18423 | 0.600 |
Why?
|
| Vesicovaginal Fistula | 1 | 2016 | 12 | 0.580 |
Why?
|
| Cystectomy | 1 | 2017 | 102 | 0.580 |
Why?
|
| Retrospective Studies | 11 | 2022 | 8496 | 0.570 |
Why?
|
| Internship and Residency | 2 | 2023 | 1010 | 0.560 |
Why?
|
| Gynecology | 1 | 2017 | 124 | 0.530 |
Why?
|
| Alcoholism | 5 | 2005 | 172 | 0.510 |
Why?
|
| Databases, Factual | 4 | 2020 | 816 | 0.490 |
Why?
|
| Azasteroids | 2 | 2012 | 5 | 0.480 |
Why?
|
| Male | 28 | 2023 | 40988 | 0.450 |
Why?
|
| Ethanol | 6 | 2006 | 249 | 0.450 |
Why?
|
| Treatment Outcome | 8 | 2022 | 7998 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 584 | 0.410 |
Why?
|
| Adult | 22 | 2023 | 25659 | 0.410 |
Why?
|
| Naltrexone | 3 | 2004 | 135 | 0.400 |
Why?
|
| Urination | 3 | 2016 | 37 | 0.400 |
Why?
|
| Urethral Diseases | 1 | 2010 | 15 | 0.370 |
Why?
|
| Prostate | 2 | 2012 | 378 | 0.370 |
Why?
|
| Alcohol Drinking | 5 | 2006 | 267 | 0.370 |
Why?
|
| Diverticulum | 1 | 2010 | 44 | 0.360 |
Why?
|
| Smoking Cessation | 3 | 2007 | 230 | 0.340 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 160 | 0.340 |
Why?
|
| Anticoagulants | 1 | 2011 | 408 | 0.320 |
Why?
|
| Operative Time | 2 | 2018 | 127 | 0.300 |
Why?
|
| Quality of Life | 3 | 2022 | 1585 | 0.290 |
Why?
|
| United States | 4 | 2023 | 6681 | 0.290 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1807 | 0.290 |
Why?
|
| Research Subjects | 1 | 2017 | 73 | 0.280 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2004 | 22 | 0.270 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2017 | 135 | 0.270 |
Why?
|
| Hydrocortisone | 4 | 2005 | 298 | 0.260 |
Why?
|
| Behavior, Addictive | 1 | 2017 | 130 | 0.250 |
Why?
|
| Comorbidity | 2 | 2020 | 944 | 0.250 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 2504 | 0.250 |
Why?
|
| Patient Dropouts | 1 | 2004 | 28 | 0.240 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 373 | 0.240 |
Why?
|
| Self-Help Groups | 1 | 2023 | 14 | 0.240 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1019 | 0.230 |
Why?
|
| Patient Selection | 1 | 2017 | 686 | 0.220 |
Why?
|
| Pelvic Floor Disorders | 1 | 2023 | 55 | 0.220 |
Why?
|
| Stress, Psychological | 3 | 2005 | 313 | 0.220 |
Why?
|
| Biomedical Research | 1 | 2017 | 376 | 0.220 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6513 | 0.220 |
Why?
|
| Organ Size | 2 | 2016 | 364 | 0.220 |
Why?
|
| Placenta Accreta | 1 | 2022 | 6 | 0.220 |
Why?
|
| Sacrococcygeal Region | 1 | 2022 | 9 | 0.220 |
Why?
|
| Tibial Nerve | 1 | 2022 | 14 | 0.220 |
Why?
|
| Balloon Occlusion | 1 | 2022 | 27 | 0.210 |
Why?
|
| Child | 2 | 2023 | 6928 | 0.210 |
Why?
|
| Urinary Retention | 1 | 2022 | 40 | 0.210 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2022 | 49 | 0.200 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 3642 | 0.200 |
Why?
|
| Prostate-Specific Antigen | 2 | 2014 | 353 | 0.190 |
Why?
|
| Urethral Stricture | 1 | 2020 | 13 | 0.190 |
Why?
|
| Crohn Disease | 1 | 2007 | 730 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2022 | 4214 | 0.190 |
Why?
|
| Risk Factors | 4 | 2017 | 5420 | 0.190 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 711 | 0.180 |
Why?
|
| Tolterodine Tartrate | 2 | 2010 | 15 | 0.180 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 394 | 0.180 |
Why?
|
| Urethra | 1 | 2020 | 113 | 0.180 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1001 | 0.170 |
Why?
|
| Surgical Flaps | 2 | 2020 | 241 | 0.160 |
Why?
|
| Education | 1 | 2018 | 58 | 0.160 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 35 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3362 | 0.160 |
Why?
|
| Medical Overuse | 1 | 2018 | 36 | 0.160 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 116 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 840 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2018 | 98 | 0.150 |
Why?
|
| Incontinence Pads | 1 | 2016 | 4 | 0.140 |
Why?
|
| Temperance | 2 | 2003 | 7 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2016 | 157 | 0.130 |
Why?
|
| Tobacco Use Disorder | 1 | 2006 | 108 | 0.130 |
Why?
|
| Cues | 1 | 2006 | 175 | 0.130 |
Why?
|
| Volatilization | 1 | 2014 | 5 | 0.130 |
Why?
|
| Central Nervous System Depressants | 1 | 2005 | 45 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 125 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2018 | 429 | 0.120 |
Why?
|
| Dutasteride | 2 | 2012 | 5 | 0.120 |
Why?
|
| Pursuit, Smooth | 1 | 2004 | 31 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2016 | 290 | 0.120 |
Why?
|
| Length of Stay | 1 | 2017 | 704 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 152 | 0.120 |
Why?
|
| Saccades | 1 | 2004 | 69 | 0.120 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2003 | 48 | 0.120 |
Why?
|
| Affect | 2 | 2003 | 386 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1578 | 0.110 |
Why?
|
| Life Change Events | 1 | 2003 | 48 | 0.110 |
Why?
|
| Finasteride | 1 | 2012 | 8 | 0.110 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 7 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2018 | 756 | 0.110 |
Why?
|
| Pituitary-Adrenal System | 1 | 2002 | 64 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2002 | 81 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2018 | 2768 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2003 | 227 | 0.100 |
Why?
|
| Personality | 1 | 2003 | 134 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2004 | 912 | 0.100 |
Why?
|
| Narcotic Antagonists | 1 | 2002 | 154 | 0.090 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2010 | 34 | 0.090 |
Why?
|
| Psychomotor Performance | 1 | 2004 | 492 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2010 | 35 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2003 | 319 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2002 | 236 | 0.090 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 116 | 0.090 |
Why?
|
| Young Adult | 2 | 2018 | 5980 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2264 | 0.090 |
Why?
|
| Motivation | 2 | 2017 | 288 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2005 | 1824 | 0.090 |
Why?
|
| Biomarkers | 1 | 2014 | 1718 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 895 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 916 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1961 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1375 | 0.070 |
Why?
|
| Age of Onset | 1 | 2007 | 310 | 0.070 |
Why?
|
| Pregnancy | 2 | 2023 | 2894 | 0.070 |
Why?
|
| Hypertension | 1 | 2003 | 1142 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1169 | 0.060 |
Why?
|
| Colpotomy | 1 | 2023 | 4 | 0.060 |
Why?
|
| Arousal | 2 | 2005 | 170 | 0.060 |
Why?
|
| Adolescent | 3 | 2018 | 8984 | 0.060 |
Why?
|
| Reference Values | 2 | 2016 | 674 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 305 | 0.060 |
Why?
|
| Iliac Artery | 1 | 2022 | 35 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2004 | 364 | 0.050 |
Why?
|
| Algorithms | 1 | 2010 | 1830 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2022 | 112 | 0.050 |
Why?
|
| Pelvic Floor | 1 | 2022 | 84 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1721 | 0.050 |
Why?
|
| Dilatation | 1 | 2020 | 48 | 0.050 |
Why?
|
| Logistic Models | 1 | 2004 | 1188 | 0.050 |
Why?
|
| Smartphone | 1 | 2020 | 36 | 0.050 |
Why?
|
| Registries | 1 | 2023 | 703 | 0.040 |
Why?
|
| Chicago | 1 | 2004 | 1380 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 403 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 2271 | 0.040 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 19 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2018 | 50 | 0.040 |
Why?
|
| Internet | 1 | 2020 | 312 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 332 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 12 | 0.040 |
Why?
|
| Psychopharmacology | 1 | 2006 | 26 | 0.040 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2016 | 13 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2022 | 2379 | 0.030 |
Why?
|
| Behavior | 1 | 2006 | 85 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2006 | 157 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 204 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 422 | 0.030 |
Why?
|
| Social Environment | 1 | 2005 | 188 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 288 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 53 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2003 | 38 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 257 | 0.030 |
Why?
|
| Hand Strength | 1 | 2003 | 51 | 0.030 |
Why?
|
| Patient Admission | 1 | 2003 | 112 | 0.030 |
Why?
|
| Speech | 1 | 2003 | 84 | 0.030 |
Why?
|
| Personality Assessment | 1 | 2003 | 98 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 747 | 0.030 |
Why?
|
| Biotransformation | 1 | 2002 | 50 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2004 | 160 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2002 | 131 | 0.030 |
Why?
|
| Psychometrics | 1 | 2003 | 327 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2002 | 596 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2002 | 684 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2002 | 502 | 0.020 |
Why?
|
| Sex Factors | 1 | 2003 | 1055 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2706 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1163 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1673 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 5214 | 0.020 |
Why?
|